Cover Image
市場調查報告書

癌症·睪丸抗原::開發中產品分析

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 364862
出版日期 內容資訊 英文 79 Pages
訂單完成後即時交付
價格
Back to Top
癌症·睪丸抗原::開發中產品分析 Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Pipeline Review, H1 2016
出版日期: 2016年06月28日 內容資訊: 英文 79 Pages
簡介

本報告提供以癌症·睪丸抗原為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

癌症·睪丸抗原 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Aduro BioTech, Inc.
  • Boehringer Ingelheim GmbH
  • Celldex Therapeutics, Inc.
  • GlaxoSmithKline Plc
  • Immune Design Corp.
  • ImmunoFrontier, Inc.
  • Kite Pharma, Inc.
  • Sanofi Pasteur SA
  • Scancell Holdings Plc
  • Vault Pharma Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0157TDB

Summary

Global Markets Direct's, 'Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Pipeline Review, H1 2016', provides in depth analysis on Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) targeted pipeline therapeutics.

The report provides comprehensive information on the Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A)
  • The report reviews Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) Overview
  • Cancer/Testis Antigen 1 is a protein encoded by CTAG1A gene is an antigen that is over expressed in many cancers but that is also expressed in normal ovary and testis tissues which makes it a good candidate for a cancer vaccine. Therapeutics Development
  • Therapeutics Development
    • Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Products under Development by Stage of Development
    • Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Products under Development by Therapy Area
    • Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Products under Development by Indication
  • Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Products under Development by Companies
  • Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Products under Development by Universities/Institutes
  • Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Companies Involved in Therapeutics Development
    • Aduro BioTech, Inc.
    • Boehringer Ingelheim GmbH
    • Celldex Therapeutics, Inc.
    • GlaxoSmithKline Plc
    • Immune Design Corp.
    • ImmunoFrontier, Inc.
    • Kite Pharma, Inc.
    • Sanofi Pasteur SA
    • Scancell Holdings Plc
    • Vault Pharma Inc.
  • Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Drug Profiles
    • ADU-623 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-1361849 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CDX-1401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Inhibit NY ESO-1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CMB-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2241658A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMF-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMM-65 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LV-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SCIB-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Acute Myeloid Leukemia and Myelodysplastic Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VCP-2292 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPI-111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Dormant Projects
  • Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Discontinued Products
  • Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Featured News & Press Releases
    • Jun 08, 2016: Immune Design Announces Updated Results For Its Immuno-oncology Product Candidate LV305 at ASCO
    • Jun 08, 2016: Immune Design Announces Updated Results For Immuno-oncology Product Candidate CMB305 At ASCO
    • Jun 04, 2016: Celldex Therapeutics' CDX-1401, CDX-301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma
    • Apr 21, 2016: Immune Design Announces Presentation on LV-305 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
    • Apr 18, 2016: Celldex Therapeutics Presents Poster on CDX-1401 at the AACR Annual Meeting 2016
    • Feb 09, 2016: Immune Design Announces Positive Topline Data From Phase 1 Clinical Trial of CMB305
    • Jan 08, 2016: Immune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305
    • Nov 11, 2015: Immune Design Announces Start of Randomized Phase 2 Cancer Immunotherapy Combination Trial in Patients With Soft Tissue Sarcoma
    • Aug 12, 2015: Immune Design Announces Phase 2 Cancer Immunotherapy Trial Collaboration
    • Jun 01, 2015: Aduro Biotech Announces ASCO Presentation of Encouraging Data From Ongoing Phase 1b Clinical Trial of Its Immunotherapy for the Treatment of Mesothelioma
    • May 13, 2015: Immune Design Announces Positive Data from Phase 1 Studies On LV305 at the 2015 American Society of Clinical Oncology Annual Meeting
    • May 13, 2015: Immune Design To Present Positive Phase 1 Data From On G305 at the 2015 American Society of Clinical Oncology Annual Meeting
    • Mar 31, 2015: Immune Design Announces Positive Topline Data From Phase 1 Clinical Trials of Immuno-Oncology CMB305 Agent
    • Mar 26, 2015: Immune Design Announces Treatment of Patients With CMB305 Investigational Immuno-Oncology Agent
    • Jun 05, 2014: Immune Design Announces Treatment of First Patient in Phase 1 Clinical Trial of LV305 Immuno-Oncology Agent
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Aduro BioTech, Inc., H1 2016
  • Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Pipeline by Celldex Therapeutics, Inc., H1 2016
  • Pipeline by GlaxoSmithKline Plc, H1 2016
  • Pipeline by Immune Design Corp., H1 2016
  • Pipeline by ImmunoFrontier, Inc., H1 2016
  • Pipeline by Kite Pharma, Inc., H1 2016
  • Pipeline by Sanofi Pasteur SA, H1 2016
  • Pipeline by Scancell Holdings Plc, H1 2016
  • Pipeline by Vault Pharma Inc., H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Dormant Projects (Contd..2), H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top